Physician profile
Hannah Devazier
NPI 1720552755
$3,024.45
in general payments reported to CMS, 2019-2025
26 companies · $337 in 2025
The $337 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $380 · 2022: $645 · 2023: $553 · 2024: $1,109 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,999.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $857.72 | 2021-2025 | |
| Novo Nordisk INC | $401.73 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $343.60 | 2022-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $255.00 | 2022-2024 | |
| Lilly USA, LLC | $224.75 | 2021-2024 | Mounjaro, Zepbound |
| Pfizer INC. | $105.52 | 2023-2024 | |
| Shield Therapeutics INC | $92.94 | 2024-2025 | |
| Inspire Medical Systems, INC. | $86.14 | 2024-2025 | Inspire |
| Phathom Pharmaceuticals, INC. | $76.94 | 2024 | Voquezna |
| Paratek Pharmaceuticals, INC. | $72.79 | 2025 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.19 | 2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company Ltd. | $72.11 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $57.20 | 2021-2022 | |
| Amgen INC. | $46.58 | 2024-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $36.03 | 2024 | Trelegy Ellipta, Arexvy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $34.12 | 2025 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.02 | 2025 | Lifevest |
| Galderma Laboratories, L.P. | $23.34 | 2024 | Dysport |
| Dexcom, INC. | $23.13 | 2021 | |
| Ironwood Pharmaceuticals, INC | $19.61 | 2023 | Linzess |
| Merck Sharp & Dohme LLC | $16.80 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Sanofi Pasteur INC. | $15.30 | 2022 | |
| Genentech USA, INC. | $15.20 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.76 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.12 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.81 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Devazier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.